Quiet Therapeutics Overview
- Year Founded
-
2010
- Status
-
Out of Business
- Employees
-
4
- Latest Deal Type
-
Liquidation
Quiet Therapeutics General Information
Description
Developer of cancer drugs designed to specifically target tumor cells. The company's drugs utilize its proprietary GAGomer technology that target the specific cancer cells, that leads to the death of the cancer cells, enabling healthcare providers to cure their patients and improve their lives.
Contact Information
Website
www.quietx.comCorporate Office
- 18 Einstein Street, 5th floor
- POB: 4053
- Ness Ziona 74140
- Israel
Corporate Office
- 18 Einstein Street, 5th floor
- POB: 4053
- Ness Ziona 74140
- Israel
Quiet Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 4. Bankruptcy: Liquidation | 01-Jan-2017 | Completed | Out of Business | |||
| 3. Later Stage VC | 01-Apr-2015 | Completed | Startup | |||
| 2. Grant | 01-Nov-2013 | $2.86M | $5.5M | Completed | Startup | |
| 1. Early Stage VC | 15-Jan-2013 | $5.5M | $5.5M | Completed | Startup |
Quiet Therapeutics Comparisons
Industry
Financing
Details
Quiet Therapeutics Competitors (51)
One of Quiet Therapeutics’s 51 competitors is TOLREMO therapeutics, a Venture Capital-Backed company based in Basel, Switzerland.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| TOLREMO therapeutics | Venture Capital-Backed | Basel, Switzerland | ||||
| Macomics | Venture Capital-Backed | Edinburgh, United Kingdom | ||||
| CV6 Therapeutics | Venture Capital-Backed | Belfast, United Kingdom | ||||
| T3 Pharmaceuticals | Formerly VC-backed | Allschwil, Switzerland | ||||
| Meditope Biosciences | Venture Capital-Backed | Pasadena, CA |
Quiet Therapeutics Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Quiet Therapeutics Patents
Quiet Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2013250767-A1 | Lipidated glycosaminoglycan particles for the delivery of nucleic acids | Inactive | 18-Apr-2012 | ||
| CA-2868238-A1 | Lipidated glycosaminoglycan particles for the delivery of nucleic acids | Inactive | 18-Apr-2012 | ||
| EP-2839015-A1 | Lipidated glycosaminoglycan particles for the delivery of nucleic acids | Active | 18-Apr-2012 | ||
| EP-2839015-B1 | Lipidated glycosaminoglycan particles for the delivery of nucleic acids | Inactive | 18-Apr-2012 | A61K9/16 |
Quiet Therapeutics Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Quiet Therapeutics FAQs
-
When was Quiet Therapeutics founded?
Quiet Therapeutics was founded in 2010.
-
Where is Quiet Therapeutics headquartered?
Quiet Therapeutics is headquartered in Ness Ziona, Israel.
-
What is the size of Quiet Therapeutics?
Quiet Therapeutics has 4 total employees.
-
What industry is Quiet Therapeutics in?
Quiet Therapeutics’s primary industry is Drug Delivery.
-
Is Quiet Therapeutics a private or public company?
Quiet Therapeutics is a Private company.
-
What is Quiet Therapeutics’s current revenue?
The current revenue for Quiet Therapeutics is .
-
How much funding has Quiet Therapeutics raised over time?
Quiet Therapeutics has raised $17.5M.
-
Who are Quiet Therapeutics’s competitors?
TOLREMO therapeutics, Macomics, CV6 Therapeutics, T3 Pharmaceuticals, and Meditope Biosciences are some of the 51 competitors of Quiet Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
